# Safety of endovascular therapy in ischemic stroke patients ⩾90 years: A cohort study from the EVA-TRISP collaboration

**Authors:** Jasmine Jost, Lukas Enz, Martina B Goeldlin, Philipp Baumgartner, Davide Strambo, Nabila Wali, Nicolas Martinez-Majander, Georg Kägi, Laura Vandelli, Christoph Riegler, Danna Krupka, Matteo Paolucci, Mauro Magoni, Giovanni Bianco, Hamza Jubran, Dejana R Jovanovic, Tomas Klail, Laura P Westphal, Alexander Salerno, Leon A Rinkel, Laura Mannismäki, Tolga Dittrich, Livio Picchetto, Regina von Rennenberg, Miguel Serôdio, Stefano Forlivesi, Dikran Mardighian, Carlo W Cereda, Ronen R Leker, Visnja Padjen, Mira Katan, Marios-Nikos Psychogios, Urs Fischer, Tomas Dobrocky, Mirjam R Heldner, Patrik Michel, Paul J Nederkoorn, Sami Curtze, Gian Marco De Marchis, Guido Bigliardi, Christian H Nolte, João Pedro Marto, Andrea Zini, Alessandro Pezzini, Susanne Wegener, Marcel Arnold, Stefan T Engelter, Henrik Gensicke

PMC · DOI: 10.1093/esj/23969873251360607 · European Stroke Journal · 2026-01-01

## TL;DR

This study finds that endovascular therapy in stroke patients aged 90 and older has higher risks of poor outcomes and death, but does not increase the risk of bleeding in the brain.

## Contribution

The study provides new evidence on the safety of endovascular therapy in patients aged 90 and older, showing outcomes and risks compared to younger patients.

## Key findings

- Patients aged 90 and older had higher odds of poor functional outcomes after endovascular therapy.
- The elderly group had higher mortality rates and unsuccessful recanalization compared to younger patients.
- Symptomatic intracranial hemorrhage risk was not increased in patients aged 90 and older.

## Abstract

Data on safety of endovascular therapy (EVT) in the very elderly are scarce. Using data from a large prospective EVT registry, we aimed at providing better evidence for EVT decision-making in patients aged 90 years and older.

In this multicentre observational study from the EVA-TRISP collaboration outcomes were compared between patients aged ⩾90 years with those aged <90 years using multivariate logistic regression analysis and reporting odds ratios and 95% confidence intervals. Outcomes were occurrence of poor functional outcome in survivors (modified Rankin Scale (mRS) 3–5 if pre-stroke mRS 0–2 and mRS higher than pre-stroke mRS if pre-stroke mRS 3–5), mortality at 3 months after stroke, unsuccessful recanalization (mTICI 0–2a) and symptomatic intracranial hemorrhage (sICH, defined by ECASS-II-/III-criteria).

Of 13,306 eligible patients, 892 were ⩾90 years old (6.7%). The very elderly had a higher median National Institutes of Health Stroke Scale (NIHSS) on admission (16 vs 14) and were more likely to have a pre-stroke mRS of 3–5 (38.0% vs 8.7%). The odds of poor functional outcome (ORadjusted 2.35 (95%-CI 1.87–2.97); 61.6% vs 38.7%), death (ORadjusted 3.04 (95%-CI 2.60–3.55); 53.9% vs 21.3%) and unsuccessful recanalization (ORadjusted 1.34 (95%-CI 1.14–1.57); 32.4% vs 27.2%) were higher in patients aged ⩾90 years. The odds of sICH did not differ (ORadjusted 0.92 (95%-CI 0.66–1.28); 5.1% vs 5.0%).

EVT-treated stroke patients ⩾90 years had higher odds of poor functional outcome, mortality and unsuccessful recanalization than younger patients. However, the probability of sICH after EVT was not increased. The decision in favor of or against EVT in the very elderly should not be based on age alone.

Graphical abstract

## Linked entities

- **Diseases:** ischemic stroke (MONDO:1060198)

## Full-text entities

- **Diseases:** death (MESH:D003643), intracranial hemorrhage (MESH:D020300), ischemic stroke (MESH:D002544), Stroke (MESH:D020521)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866211/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866211/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866211/full.md

---
Source: https://tomesphere.com/paper/PMC12866211